[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598744":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":35,"collaborators":7,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Deciphera Pharmaceuticals, LLC","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Clinical Team","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","888-724-3274","clinicaltrials@deciphera.com",[18],{"facility":19,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Synexus Clinical Research, US INC","RECRUITING","Wilmington","North Carolina","28401","United States","US",{"type":27,"coordinates":28},"Point",[29,30],-77.94604,34.23556,{"lat":30,"lon":29},[33],{"name":7,"role":14,"phone":34,"phoneExt":7,"email":7},"888-581-9246",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100598744","move-tenosynovial-giant-cell-tumor-tgct-real-world-participant-experience-with-vimseltinib-100598744",false,"NCT07075471","MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib","Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor (MOVE)","MOVE","Inclusion Criteria:\n\n1. Diagnosis of TGCT according to medical records\n2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.\n3. Has provided informed consent and medical records release\n\nExclusion Criteria:\n\n1\\. Participant is active in an interventional clinical trial of vimseltinib","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.\n\nThis study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.",[54],"Tenosynovial Giant Cell Tumor","2026-07-24",{"date":57,"type":58},"2026-07-27","ACTUAL",{"date":60,"type":58},"2025-09-03",{"date":62,"type":49},"2027-09",{"name":5,"class":6},1]